Do fluoride supplements harm children? FDA panel discussion turns into heated debate
Pediatric dentists consider the chewable tablets, available only by prescription, as particularly important for families who live in areas without fluoride in drinking water, who don't have dental insurance or who can't afford regular visits to dentists.
Under Commissioner Marty Makary, however, the FDA has been taking steps to remove fluoride supplements from the market. A final decision isn't expected until October, although advocates and critics at the meeting didn't agree on basic scientific methods or even responsible dental practices.
During the public meeting held in Silver Spring, Maryland, dental experts outlined the careful balance of getting the right amount of fluoride to their patients. Too little can result in weakened tooth enamel, said Dr. James Bekker, a member of the Utah Dental Association. Too much can lead to fluorosis, a condition that leaves white or brown spots on the teeth.
'There are areas where we have community water fluoridation. We don't need supplements in those areas,' said Bekker, who was invited to speak at Wednesday's meeting. 'But there are many areas of our country where we either don't have community water fluoridation or we don't have naturally occurring fluoride. In those places, supplements are the key to achieving that balance.'
A panelist, Dr. Bill Osmunson, a retired dentist who now works for the Fluoride Action Network, an anti-fluoride group, peppered Bekker about how he determines whether a child needs fluoride supplements.
'You ask where they live?' Osmunson asked. 'You ask where they go to school?'
Bekker explained how he does comprehensive assessments of his young patients, including reviewing dietary issues and whether they use other supplements, before he prescribes the fluoride tablets or drops.
'Really, you ask all those questions?' Osmunson said.
'You bet,' Bekker said.
Osmunson's 'inquisition of Dr. Bekker was a tactic to attempt to make him look incompetent,' said Dr. Johnny Johnson, president of the American Fluoridation Society. 'That type of exchange is meant as a popularity contest.' Johnson spoke in favor of the supplement during a public comment session.
Osmunson and other critics relied on data that didn't necessarily prove their criticism of the products.
For example, Makary, the FDA commissioner, has said ingested fluoride alters the gut microbiome. His assertion appears to hinge on a 2023 review of research by scientists in Ireland.
That analysis noted that animal studies suggested that ingesting fluoride affected the microbiome but that none of the studies examined fluoride and the human microbiome. The researchers concluded that any possible effect of fluoride on the microbiome is 'still in its early days, and studies investigating the impact of fluoride on the human microbiome have only begun to appear in the literature.'
One of the authors of that study also spoke at Wednesday's meeting. 'Fluoride consumption at levels which we consider good for maintaining good oral health probably have limited impact on the oral and gut microbiomes,' said Gary Moran of Trinity College Dublin in Ireland. But, he added, 'we certainly need more studies.'
There was no vote for or against fluoride supplements.
Dr. David Krol, a representative of the American Academy of Pediatrics, spoke in favor of fluoride supplements as one of many tools physicians need to ensure their patients' teeth are as strong as possible.
'Fluoride supplementation, as well as conversations about diet and conversations about hygiene, are the kinds of things that take place between pediatricians and patients,' Krol said. 'We have to have that opportunity to continue those conversations and have those multifactorial tools to address this disease.'
Even though Medicaid covers oral health for children, fewer than half went to the dentist at least once a year.
Cavities that erupt in those kids' mouths get worse if they're left untreated, and they can cause widespread damage. The decay 'eats away at the bone' around the tooth and sometimes gets into the bloodstream, said Dr. Steven Levy, a professor of preventive and community dentistry at the University of Iowa.
'This is more than just a garden-variety, middle-class person's experience with a cavity,' he said.
Major public health groups, including the American Academy of Pediatrics and the U.S. Preventive Services Task Force, recommend prescribing supplements for children starting at 6 months if the water supply isn't fluoridated.
Fluoride supplements are often given to kids from age 5 until they have their permanent teeth, around age 13 or 14, Bekker said in an interview before the meeting. Babies get drops until they're old enough to chew tablets. They're generally inexpensive.
Over-the-counter vitamins and supplements don't contain fluoride. Fluoride is available over the counter only in toothpaste and mouthwashes.
Makary also objects to the fluoride supplements because they aren't approved by the FDA. Because the supplements had been in use for decades before Congress mandated that drug manufacturers show that their products were not only safe but also effective, they were never required to go through the approval process. For almost as long as the supplements have been prescribed, critics have been concerned about the lack of rigorous data showing their potential health effects and how they protect kids' teeth.
'I think we really need to understand the benefits,' said Linda Birnbaum, a toxicologist and former director of the National Institute of Environmental Health Sciences and the National Toxicology Program. Birnbaum also spoke during the FDA meeting.
Dr. Brett Kessler of the American Dental Association acknowledged that prescription fluoride supplements should be administered only after a 'thoughtful decision' based on conversations between physicians and families.
'I'm hoping we can all take a breath, filter out all the noise and not give in to the anti-fluoride hysteria,' he said during the meeting.
This article was originally published on NBCNews.com
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
RFK Jr. pulls funding for mRNA vaccines as scientists pursue breakthrough treatments for HIV, cancer, the flu and more
Health Secretary Robert F. Kennedy Jr. announced Tuesday that the federal government is canceling nearly $500 million in funding for the development of mRNA vaccines, a revolutionary new technology that was first put into widespread use during the COVID-19 pandemic. In a video explaining the decision posted to social media, Kennedy said that the Department of Health and Human Services has determined that 'mRNA technology poses more risk than benefits' for respiratory viruses like COVID-19. He also claimed that the pandemic showed 'mRNA vaccines don't perform well against viruses that affect the upper respiratory tract.' That statement runs counter to a wide body of research finding that COVID vaccines saved millions — if not tens of millions — of lives over the course of the pandemic. A total of 22 projects funded by a government agency called the Biomedical Advanced Research and Development Authority (BARDA) will be affected by the funding freeze, according to the department. A few projects that are in their final stages will be allowed to continue, but 'no new mRNA-based projects will be initiated.' 'This isn't just about vaccines. It's about whether we'll be ready when the next crisis hits. Cutting mRNA development now puts every American at greater risk,' Rick Bright, who directed BARDA in the early stages of the pandemic before being reassigned by the Trump administration, told NBC News. The decision doesn't mean that research into mRNA vaccines will stop entirely, but it does cut off a major source of funding that helped the vaccines become a reality in the first place. By the time the pandemic had started, the government had already given an estimated $337 million in grants for research into mRNA vaccines. That support over the course of decades put scientists in a position to make COVID vaccines available to the public at a record-shattering pace of less than a year. How do mRNA vaccines work? The 'm' in mRNA stands for messenger. In the most basic terms, it's a piece of genetic code that tells our cells what to do. Scientists have discovered how to harness this process to make vaccine development much faster and less expensive. Traditional vaccines typically use a dead or weakened version of a virus to stimulate an immune response that effectively teaches the body how to combat the real version if it ever encounters it. These types of vaccines can take a long time to develop because they rely on the slow, often complicated process of cultivating and modifying the actual virus into a safe and effective form. Using mRNA is much faster because the crucial ingredients can be created and customized in a lab. It took Moderna just two days to produce its mRNA vaccine for COVID in January 2020, before most people had ever even heard of the virus. The vaccines carry a snippet of mRNA that instructs the body to produce a small portion of a virus, usually a protein on its outer membrane, which is enough to trigger the same type of immune response that is prompted by traditional vaccines. The quicker process also means that existing mRNA vaccines can be modified more rapidly when viruses evolve. Despite Kennedy's claims, mRNA-based COVID vaccines have been found to be just as effective at preventing severe infections and death as vaccines made using other methods. After the vaccines became widely available, unvaccinated people were 11 times more likely to die of COVID than those who were fully vaccinated, according to data from the Centers for Disease Control and Prevention. Two researchers who helped achieve early breakthroughs in mRNA vaccines were awarded the Nobel Prize in 2023. Applications beyond COVID The introduction of COVID vaccines didn't just mark a turning point in the deadliest pandemic in modern history. It also provided evidence of mRNA's potential to protect people from a whole range of diseases. Just last week, researchers released promising results from early trials of new mRNA-based vaccines for HIV, a huge breakthrough in a pursuit that has confounded scientists for more than 40 years. There have been tremendous strides made in drugs that protect people from catching the virus or keep them healthy if they do contract it, but the limitations of those treatments still mean that more than 600,000 people are dying every year of AIDS — mostly in the developing world. Experts see a potential vaccine as a key to finally conquering the virus. There is also optimism that mRNA could be an effective tool in combating the seasonal flu. Current flu vaccines vary widely in effectiveness from year to year, and are only about 60% effective at their best, because it can be hard for experts to predict which strain of the virus will be more dominant in any given flu season. Several pharmaceutical companies are developing mRNA flu vaccines that could become a powerful tool for fighting influenza because of how quickly they can be adapted to match the nature of the virus at any given time. That speed could be especially important if a novel flu strain, like bird flu, causes a severe outbreak. There is even some promise that mRNA might one day be used to make a universal flu vaccine that covers all strains. The holy grail for mRNA is cancer. Though vaccines are typically used to prevent disease, there are several vaccines in development that show 'real hope' of being an effective treatment for people with cancer. Those include 'individualized' vaccines that are custom-made for each patient's specific needs. An mRNA vaccine for RSV is already available to certain high-risk adults. Other possible applications include the Zika virus and cytomegalovirus, an infection that is particularly dangerous for babies and people with compromised immune systems. Though experts say the rollback of U.S. government funding is a setback for these projects, some also expressed optimism that mRNA breakthroughs will continue to come even without America's support. 'Will this dent what's going on in the U.S.? Unquestionably,' Kate Bingham, who led the United Kingdom's COVID vaccine task force, told the Guardian. 'Does that mean it's negative for the world? Not necessarily.' Solve the daily Crossword


Fast Company
27 minutes ago
- Fast Company
Sources reveal the Trump administration's plans for cutting U.S. drug prices
The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and elsewhere in order to cut drug costs in the United States, according to a White House official and three pharmaceutical industry sources. U.S. officials told drug companies it would support their international negotiations with governments if they adopt 'most favored nation' pricing under which U.S. drug costs match the lower rates offered to other wealthy countries, the White House official said. The U.S. is currently negotiating bilateral trade deals and setting tariff rates on the sector. The Trump administration has asked some companies for ideas on raising prices abroad, two of the sources said, describing multiple meetings over several months aimed at lowering U.S. prices without triggering cuts to research and development spending drugmakers insist would result. The White House official called the effort collaborative, saying both sides were seeking advice from each other. The U.S. pays more for prescription drugs than any other country, often nearly three times as much as other developed nations. President Donald Trump has repeatedly said he wants to narrow this gap to stop Americans from being 'ripped off.' The previously unreported discussions reflect the challenges Trump faces to achieve that goal, and are the backdrop to the letters he sent last week to CEOs of 17 major drugmakers, urging them to cut U.S. prices to match those paid overseas. Unlike in the U.S., where market forces determine drug prices, European governments typically negotiate directly with companies to set prices for their national healthcare systems. Anna Kaltenboeck, a health economist at Verdant Research, said European nations have leverage to drive pricing and are sometimes willing to walk away from purchasing medicines they deem too expensive. Drugmakers generate most of their sales in the U.S. The Pharmaceutical Research and Manufacturers of America — the industry's main lobby group — has always argued that cutting U.S. prices would stifle innovation by lowering R&D spending. PhRMA declined to comment on the private meetings. Kaltenboeck said past studies had shown that drugmakers made enough money in the U.S. to more than fund their entire global R&D spends. 'Prices can come down in the United States without being increased in other countries, and we can still get innovation,' she said. TOP PRIORITY Despite the Trump administration's tariff threats and pressure to move more manufacturing to the U.S., the push to raise European drug prices is its top priority in discussions with industry, according to a senior executive at a European drugmaker, who spoke on condition of anonymity about the confidential meetings. 'This is the key conversation right now with PhRMA and every company getting that message from Pennsylvania Avenue to a point that we are already executing on it,' the executive said, referring to the White House address. The company had already met with European governments on the issue, the executive added. An E.U. Commission spokesperson said it is in regular contact with the pharma industry and pointed to an agreement with the U.S. that should it impose tariffs on pharmaceuticals, they would be capped at 15%. When asked how the administration would support international drug price negotiations, the White House official referred Reuters to Trump's most favored nation executive order from May. That order directed trade officials to pursue trade and legal action against countries keeping drug prices below fair market value. In last week's letters, Trump complained that since the May executive order, most industry proposals had simply shifted blame for high prices or requested policy changes that would result in billions in industry handouts. A second source, a pharmaceutical executive who was not authorized to speak on the matter, said the Trump administration has been continually meeting with representatives of his company and had discussed strategies for raising drug prices internationally. 'There's a big push from the administration to drive up prices outside the U.S.,' the executive said. The executive said the Trump administration had been looking at using trade talks with the UK and EU as leverage, and considered pressuring countries to spend a higher percentage of GDP on new medicines or offering tariff breaks in exchange for higher drug spending. It was understood that the UK deal specifically aims to get the country to ramp up investment in branded medicines over time, the executive said. A spokesperson for the UK government said it would continue to work closely with the U.S. and its own pharmaceutical industry to understand the possible impact of any changes to drug pricing, without commenting on the trade talks. In April, over 30 industry CEOs including those from AstraZeneca, Bayer and Novo Nordisk signed a letter to European Union President Ursula von der Leyen saying Europe needed to rethink its pricing policies. 'It's going to be very difficult for a country that already has the ability to control what it spends to go in the other direction,' Kaltenboeck said, 'and it doesn't make much sense for them politically.'


CBS News
28 minutes ago
- CBS News
Weiss Hospital could face closure when kicked off Medicare, Medicaid Friday, report says
Weiss Hospital in Chicago's Uptown neighborhood will be removed from the Medicare and Medicaid programs Friday, and a report suggests it could face closure. The Department of Health and Human Services is removing Weiss from the federal health care programs, saying the hospital failed to meet their standards of care. A nurse in the hospital's Emergency Department told the Chicago Sun-Times they expect to shut down Friday morning at 7 a.m. They said they were informed of that decision by their supervisor, and also noted no staff schedule has been set beyond Saturday. CBS News Chicago has leaned more about the exact reasons the hospital was deemed noncompliant with federal rules. Notably, a July 12 report by the Centers for Medicare and Medicaid Services did not cite the hospital's broken air conditioning as a reason. Rather, the report detailed multiple failures related to nursing care, along with a failure related to pharmaceutical record-keeping.